Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 1, 2024BMJOpen Access

5PSQ-015 Analysis of the occurrence of atrial fibrillation with the administration of ibrutinib: should we be careful with this drug?

View Full Paper
Ask AI
Bookmark
Share

Authors

BRB Sánchez RodríguezDTD Gámez TorresVRV González Rosa

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Rodríguez et al. (2024) studied this question.

synapsesocial.com/papers/68e7660bb6db6435876dba21https://doi.org/10.1136/ejhpharm-2024-eahp.349
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study2018 · 45 citations
  2. 2The cardiac toll of ibrutinib: exploring atrial fibrillation in treated patients2025
  3. 3Ibrutinib and atrial fibrillation: An in-depth review of clinical implications and management strategies2024 · 2 citations
  4. 4Cardiotoxicity in ibrutinib-treated patients: incidence, management, and impact on treatment outcomes2025
  5. 55PSQ-038 Real-world safety of ibrutinib in clinical practice in patients with chronic lymphocytic leukaemia2024